Synthesis and characterization of Cr(III) complexes with 3-hydroxy-4-pyrones and 1,2-dimethyl-3-hydroxy-4-pyridinone (DMHP): X-ray crystal structures of Cr(DMHP)3·12H2O and Cr(ma)3

Synthesis and Reactivity in Inorganic, Metal-Organic and Nano-Metal Chemistry

Volumn 35, Issue 1, 2005, Pages 61-70

  Hsieh, Wen Yuan ^a   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PYRONE DERIVATIVE; ALUMINUM; CHROMIUM; CHROMIUM CHLORIDE; CHROMIUM DERIVATIVE; DEFERIPRONE; ETHYLMALTOL; GALLIUM; INDIUM; IRON COMPLEX; MALTOL; MANGANESE; METAL COMPLEX; OXYGEN; PYRIDONE DERIVATIVE; TRIETHYLAMINE; WATER;

ARTICLE; ELECTROCHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; GEOMETRY; INFRARED RADIATION; ISOMERIZATION; OXIDATION REDUCTION POTENTIAL; SYNTHESIS; ULTRAVIOLET RADIATION; X RAY CRYSTALLOGRAPHY;

EID: 18244384700     PISSN: 15533174     EISSN: None     Source Type: Journal    
DOI: 10.1081/SIM-200047549     Document Type: Article

References (40)

1. Ahmed, S. I.; Burgess, J.; Fawcett, J.; Parson, S. A.; Russell, D. R.; Laurie, S. H. The Structures of Bis-maltolato-zinc(II) and of Bis-3-hydroxy-1,2-dimethyl-4-pyridinonato-zinc(II) and -Lead(II). Polyhedron 2000, 19, 129-135.
2. Ahmet, M. T.; Frampton, C. S.; Silver, J. A Potential Iron Pharmaceutical Composition for the Treatment of Iron-deficiency Anemia. The Crystal and Molecular Structure of Mer-tris-(3-hydroxy-2-methyl-4H-pyran-4-onato)Iron(III). J. Chem. Soc. Dalton Trans. 1988, 1159-1163.
3. Anderson, R. A. Chromium in the Prevention and Control of Diabetes. Diabetes Metab. 2000, 26, 22-27.
4. 2. Inorg. Chem. 2001, 40, 4384-4388.
5. Bernstein, L. R.; Tanner, T.; Godfrey, C.; Noll, B. Chemistry and Pharmacokinetics of Gallium Maltolate, a Compound with High Oral Gallium Bioavailability. Metal Based Drugs 2000, 7, 33-47.
6. Burla, M. C.; Camalli, M.; Carrozzini, B.; Cascarano, G. L.; Giacovazzo, C.; Polidori, G.; Spagna, R. SIR2002: The Program. J. Appl. Cryst. 2003 (36), 1103.
7. Caravan, P.; Gelmini, L.; Glover, N.; Herring, F. G.; Li, H.; McNeill, J H.; Rettig, S. J.; Styawati, I. A.; Shuter, E.; Sun, Y.; Tracey, A. S.; Yuen, V. G.; Orvig, C. Reaction Chemistry of BMOV. Bis(maltolato)oxovanadium(IV), A Potent Insulin Mimetic Agent. J. Am. Chem. Soc. 1995, 117, 12759-12770.
8. Clarke, E. T.; Martell, A. E.; Reibenspies, J. Crystal Structure of the Tris 1,2-dimethyl-3-hydroxy-4-pyridinone (DMHP) Complex with the Fe(III) ion. Inorg. Chim. Acta 1992, 196, 177-183.
9. Codd, R.; Dillon, C. T.; Levina, A.; Lay, P. A. Studies on the Genotoxicity of Chromium: From Test Tube to the Cell. Coord. Chem. Rev. 2001, 216/217, 533-577 (references therein).
10. Cohen, A. R.; Galanello, R.; Piga, A.; DiPalma, A.; Vullo, C.; Tricta, F Safety Profile of the Oral Iron Chelator Deferiprone: A Multicentre Study. Brit. J. Haematol. 2000, 108, 305-312.
11. +3 - Crystal and Molecular Structures of 3-hydroxy-2(1H)- pyridinone and Tris[3-hydroxy-2(1H)-pyridinonato]chromium(III). Z. Anorg. Allg. Chem. 2000, 626, 1545-1549.
12. 99mTc Radiopharmaceuticals for Renal Imaging: Tris(N-substituted-3-hydroxy-2-methyl-4-pyridinonato) technetium(IV) Cations. Nucl. Med. Biol. 1993, 20, 857-863.
13. Edwards, D. S.; Liu, S.; Poitier, M. J.; Zhang, H.; Webb, G. A.; Orvig, C. Characterization of tris(N-substituted-3-hydroxy-2-methyl-4-pyridinonato) technetium(IV) Cations. Inorg. Chem. 1994, 33, 5607-5679.
14. Finnegan, M. M.; Rettig, S. J.; Orvig, C. A Neutral Water-soluble Aluminum Complex of Neurological Interest. J. Am. Chem. Soc. 1986, 108, 5033-5035.
15. Hepburn, D. D. D.; Burney, M.; Woski, S. A.; Vincent, J. B. The Nutritional Supplement Chromium Picolinates Generates Oxidative DNA Damage and Peroxidized Lipids In Vivo. Polyhedron 2003, 22, 455-463.
16. 2O (DMHP = 1,2-dimethyl-3-hydroxy-4- pyridinone). Inorg. Chem. Submitted to.
17. Levina, A.; Codd, R.; Dillon, C. T.; Lay, P. A. Chromium in Biology: Toxicology and Nutritional Aspects. Prog. Inorg. Chem. 2003, 51, 145-250 (references therein).
18. Levina, A.; Lay, P. A. Mechanistic Studies of Relevance to the Biological Activities of Chromium. Coord. Chem. Rev. 2004, submitted.
19. Liu, Z. D.; Hider, R. C. Design of Clinically Useful Iron(III)-selective Chelators. Med. Res. Rev. 2002a, 1, 26-64 (references therein).
20. Liu, Z. D.; Hider, R. C. Design of Iron Chelators With Therapeutic Application. Coord. Chem. Rev. 2002b, 232, 151-171 (references therein).
21. Matsuba, C. A.; Nelson, W. O.; Rettig, S. J.; Orvig, C. Neutral Water-soluble Indium Complexes of 3-hydroxy-4-pyrones and 3-hydroxy-4- pyridinones. Inorg. Chem. 1988, 27, 3935-3939.
22. McNeill, J. H.; Yuen, V. G.; Hoveyda, H. R.; Orvig, C. Bis(maltolato) oxovanadium(IV) is a Potent Insulin Mimic. J. Med. Chem. 1992, 35, 1489-1491.
23. Morita, H.; Hayashi, Y.; Shimumora, S.; Kawaguchi, S. Synthesis and Properties of Tris(3-hydroxy-2-methyl-4-pyronato) Complexes of Chromium(III), Manganese(III) and Iron(III). Chem. Lett. 1975, 339-342.
24. 2O. A Facial Geometry Imposed by Extensive Hydrogen Bonding with the Ice I Structure. J. Am. Chem. Soc. 1987, 109, 4121-4123.
25. Nelson, W. O.; Karpishin, T. B.; Rettig, S. J.; Orvig, C. Aluminum and Gallium Compounds of 3-hydroxy-4-pyridinones: Synthesis, Characterization, and Crystallography of Biologically Active Complexes with Unusual Hydrogen Bonding. Inorg Chem. 1988, 27, 1045-1051.
26. Nelson, W. O.; Rettig, S. J.; Orvig, C. Aluminum and Gallium Complexes of 1-ethyl-3-hydroxy-2-methyl-4-pyridinone: A New Exoclathrate Matrix. Inorg. Chem. 1989, 28, 3153-3157.
27. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
28. Parajon-Costa, B. S.; Wagner, C. C.; Baran, E. J. Voltammetric and Spectroscopic Study of Chromium(III)/Picolinate Complexes. Z. Anorg. Allg. Chem. 2003, 629, 1085-1090.
29. Puerta, D. T.; Cohen, S. M. Examination of Novel Zin-binding Groups for Use in Matrix Metalloproteinase Inhibitors. Inorg. Chem. 2003, 42, 3423-3430.
30. Richardson, D. R. The Controversial Role of Deferiprone in the Treatment of Thalasemia. J. Lab. Clin. Med. 2001, 137, 324-329.
31. Shelderick, G. M. SHELXL 97. A Program for Crystal Structure Refinement. University of Göttingen: Göttingen, Germany, 1997.
32. Stearns, D. M. Is Chromium a Trace Essential Metal? BioFactors 2001, 11, 149-162.
33. Taher, A.; Sheikh-Taha, M.; Koussa, S.; Inati, A.; Neeman, R.; Mourad, F. Comparison between Deferoxamine and Deferiprone (L1) in Iron-loaded Thalassemia Patients. Eur. J. Haematol. 2001, 67, 30-34.
34. Thompson, K. H.; Orvig, C. Design of Vanadium Compounds as Insulin Enhancing Agents. J. Chem. Soc., Dalton Trans. 2000, 2885-2892 (references therein).
35. Thompson, K. H.; Orvig, C. Coordination Chemistry of Vanadium in Metallopharmaceutical Candidate Compounds. Coord. Chem. Rev. 2001, 219, 1033-1053 (references therein).
36. Thompson, K. H.; Chiles, J.; Yuen, V. G.; Tse, J.; McNeil, J. H.; Orvig, C. Comparison of Anti-hyperglycemic Effect Amongst Vanadium, Molybdenum and Other Metal Maltol Complexes. J. Inorg. Biochem. 2004, 98, 683-690.
37. Trumbo, P.; Yates, A. A.; Schlicker, S.; Poos, M. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsinic, Boron, Chromium, Copper, Iodine, Molybdenum, Nickel, Silicon, Vanadium and Zinc. J. Am. Dietetic Association, 2001, 101, 294-301.
38. Vincent, J. B. Elucidating a Biological Role for Chromium at a Molecular Level. Acc. Chem. Res. 2000, 33, 503-510.
39. Vincent, J. B. The Bioinorganic Chemistry of Chromium(III). Polyhedron 2001, 20, 1-26.
40. Zhang, Z. H.; Lyster, D. M.; Webb, G. A.; Orvig, C. Potential gallium-67 Radiopharmaceuticals for Myocardial Imaging: tris(1-aryl-3-hydroxy-2-methyl-4- pyridinonato)gallium(III) Complexes. Nucl. Med. Biol. 1992, 19, 327-335.